Free Trial
→ I'm handing you this stock today (From Behind the Markets) (Ad)tc pixel Free LLY Stock Alerts

Eli Lilly and Company (LLY) Competitors

Eli Lilly and Company logo
$1,437.46 +5.17 (+0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$1,447.63 +10.17 (+0.71%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LLY vs. AMGN, BIIB, GILD, NVDA, and VKTX

Should you buy Eli Lilly and Company stock or one of its competitors? Eli Lilly and Company's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size.

How does Eli Lilly and Company compare to Amgen?

Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

In the previous week, Eli Lilly and Company had 41 more articles in the media than Amgen. MarketBeat recorded 133 mentions for Eli Lilly and Company and 92 mentions for Amgen. Eli Lilly and Company's average media sentiment score of 0.80 beat Amgen's score of 0.68 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
35 Very Positive mention(s)
17 Positive mention(s)
27 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Eli Lilly and Company
70 Very Positive mention(s)
23 Positive mention(s)
19 Neutral mention(s)
16 Negative mention(s)
4 Very Negative mention(s)
Positive

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$36.75B6.85$7.71B$17.2426.99
Eli Lilly and Company$65.18B20.68$20.64B$30.8146.50

Eli Lilly and Company has a net margin of 31.90% compared to Amgen's net margin of 24.14%. Amgen's return on equity of 114.99% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen24.14% 114.99% 13.47%
Eli Lilly and Company 31.90%86.76%22.03%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.2%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.5%. Amgen pays out 58.5% of its earnings in the form of a dividend. Eli Lilly and Company pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen currently has a consensus price target of $422.76, suggesting a potential downside of 9.13%. Eli Lilly and Company has a consensus price target of $1,416.64, suggesting a potential downside of 1.11%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
3 Sell rating(s)
18 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.30
Eli Lilly and Company
1 Sell rating(s)
3 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.86

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Amgen on 14 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Biogen (NASDAQ:BIIB) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Eli Lilly and Company had 104 more articles in the media than Biogen. MarketBeat recorded 133 mentions for Eli Lilly and Company and 29 mentions for Biogen. Biogen's average media sentiment score of 1.34 beat Eli Lilly and Company's score of 0.80 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
22 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Eli Lilly and Company
70 Very Positive mention(s)
23 Positive mention(s)
19 Neutral mention(s)
16 Negative mention(s)
4 Very Negative mention(s)
Positive

Eli Lilly and Company has a net margin of 31.90% compared to Biogen's net margin of 3.37%. Eli Lilly and Company's return on equity of 86.76% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Eli Lilly and Company 31.90%86.76%22.03%

Eli Lilly and Company has higher revenue and earnings than Biogen. Eli Lilly and Company is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.78$1.29B$2.34108.23
Eli Lilly and Company$65.18B20.68$20.64B$30.8146.50

Biogen has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Biogen presently has a consensus target price of $254.41, indicating a potential upside of 0.46%. Eli Lilly and Company has a consensus target price of $1,416.64, indicating a potential downside of 1.11%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Eli Lilly and Company
1 Sell rating(s)
3 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.86

87.9% of Biogen shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Biogen on 12 of the 16 factors compared between the two stocks.

How does Eli Lilly and Company compare to Gilead Sciences?

Eli Lilly and Company (NYSE:LLY) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Eli Lilly and Company had 84 more articles in the media than Gilead Sciences. MarketBeat recorded 133 mentions for Eli Lilly and Company and 49 mentions for Gilead Sciences. Eli Lilly and Company's average media sentiment score of 0.80 beat Gilead Sciences' score of 0.68 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
70 Very Positive mention(s)
23 Positive mention(s)
19 Neutral mention(s)
16 Negative mention(s)
4 Very Negative mention(s)
Positive
Gilead Sciences
27 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 1.9%. Eli Lilly and Company pays out 22.5% of its earnings in the form of a dividend. Gilead Sciences pays out -103.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and lower payout ratio.

Eli Lilly and Company has a net margin of 31.90% compared to Gilead Sciences' net margin of -12.47%. Eli Lilly and Company's return on equity of 86.76% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company31.90% 86.76% 22.03%
Gilead Sciences -12.47%-1.85%-0.61%

Eli Lilly and Company presently has a consensus price target of $1,416.64, suggesting a potential downside of 1.11%. Gilead Sciences has a consensus price target of $170.15, suggesting a potential downside of 0.42%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
3 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.86
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.79

Eli Lilly and Company has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eli Lilly and Company has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B20.68$20.64B$30.8146.50
Gilead Sciences$29.44B7.20$8.51B-$3.16N/A

Summary

Eli Lilly and Company beats Gilead Sciences on 14 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

NVIDIA (NASDAQ:NVDA) and Eli Lilly and Company (NYSE:LLY) are related large-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

NVIDIA has a net margin of 63.66% compared to Eli Lilly and Company's net margin of 31.90%. NVIDIA's return on equity of 96.04% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
NVIDIA63.66% 96.04% 71.00%
Eli Lilly and Company 31.90%86.76%22.03%

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NVIDIA$215.94B18.85$120.07B$7.9121.36
Eli Lilly and Company$65.18B20.68$20.64B$30.8146.50

65.3% of NVIDIA shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 3.9% of NVIDIA shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NVIDIA has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

NVIDIA pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.5%. NVIDIA pays out 12.6% of its earnings in the form of a dividend. Eli Lilly and Company pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. NVIDIA has raised its dividend for 1 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. NVIDIA is clearly the better dividend stock, given its higher yield and lower payout ratio.

NVIDIA presently has a consensus target price of $318.75, suggesting a potential upside of 88.69%. Eli Lilly and Company has a consensus target price of $1,416.64, suggesting a potential downside of 1.11%. Given NVIDIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe NVIDIA is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NVIDIA
0 Sell rating(s)
2 Hold rating(s)
48 Buy rating(s)
5 Strong Buy rating(s)
3.05
Eli Lilly and Company
1 Sell rating(s)
3 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, NVIDIA had 276 more articles in the media than Eli Lilly and Company. MarketBeat recorded 409 mentions for NVIDIA and 133 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.80 beat NVIDIA's score of 0.03 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NVIDIA
110 Very Positive mention(s)
41 Positive mention(s)
85 Neutral mention(s)
141 Negative mention(s)
26 Very Negative mention(s)
Neutral
Eli Lilly and Company
70 Very Positive mention(s)
23 Positive mention(s)
19 Neutral mention(s)
16 Negative mention(s)
4 Very Negative mention(s)
Positive

Summary

NVIDIA beats Eli Lilly and Company on 14 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Eli Lilly and Company (NYSE:LLY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Eli Lilly and Company had 127 more articles in the media than Viking Therapeutics. MarketBeat recorded 133 mentions for Eli Lilly and Company and 6 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.80 beat Viking Therapeutics' score of 0.66 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
70 Very Positive mention(s)
23 Positive mention(s)
19 Neutral mention(s)
16 Negative mention(s)
4 Very Negative mention(s)
Positive

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$5.40N/A
Eli Lilly and Company$65.18B20.68$20.64B$30.8146.50

Eli Lilly and Company has a net margin of 31.90% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 86.76% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -117.35% -88.87%
Eli Lilly and Company 31.90%86.76%22.03%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viking Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Viking Therapeutics currently has a consensus price target of $93.36, suggesting a potential upside of 225.76%. Eli Lilly and Company has a consensus price target of $1,416.64, suggesting a potential downside of 1.11%. Given Viking Therapeutics' higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79
Eli Lilly and Company
1 Sell rating(s)
3 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

Export
MetricEli Lilly and CompanyPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.35T$13.79B$7.89B$23.62B
Dividend Yield0.49%2.58%2.47%3.73%
P/E Ratio46.6630.2635.3530.40
Price / Sales20.756.938.403.42
Price / Cash56.1715.7522.2215.97
Price / Book33.585.004.433.76
Net Income$20.64B$2.86B$3.50B$1.08B
7 Day Performance1.36%0.03%-0.97%-0.63%
1 Month Performance22.07%-5.38%-4.07%1.06%
1 Year Performance45.57%-5.73%2.04%6.73%

Eli Lilly and Company Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.0081 of 5 stars		$1,437.46
+0.4%		$1,416.64
-1.4%		+48.4%$1.35T$65.18B46.6650,000
AMGN
Amgen
4.2432 of 5 stars		$466.01
+1.1%		$389.71
-16.4%		+43.7%$251.94B$36.75B28.9631,500
BIIB
Biogen
3.0564 of 5 stars		$253.62
+1.6%		$251.00
-1.0%		+62.1%$37.49B$9.89B108.387,500
GILD
Gilead Sciences
3.3379 of 5 stars		$170.68
+3.1%		$169.19
-0.9%		+44.6%$211.64B$29.44BN/A17,000
NVDA
NVIDIA
4.9607 of 5 stars		$204.64
-4.2%		$321.47
+57.1%		-15.1%$4.93T$215.94B25.8742,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 11/11/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...
TradeWins | Sponsoredtc pixel